U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07654972) titled 'A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy' on June 12.
Brief Summary: The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it.
Participation in this study will last about 35 to 45 weeks (7 to 11 months).
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: LY4174794
Administered SC.
DRUG: LY4174...